Alfonso Iorio, on behalf of the working group

Slides:

Advertisements

Similar presentations

Vilnius, 29 June 2007 CIOMS Recommendations on Ethics in Medical Research The Eighth Global Forum on Bioethics in Research Gottfried Kreutz Dr. med., Dipl.-Chem.;

Advertisements

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

The golden standard or fools gold Selective data, impact on safety Clinical trials on trial HAI Europe Open Seminar 2008 Neues Stadthaus, Berlin, 21 November.

WAPPS – Web-based Application for a Population Pharmacokinetic Service

Real-World Prophylaxis Experience: Perspectives from Clinical Practice Alfonso Iorio MD, PhD McMaster University Canada BeneF IX ® (nonacog alfa) is not.

Systematic review of the published evidence on the pharmacokinetic characteristics of factor VIII and IX concentrates Xi M, Navarro-Ruan T, Mammen S, Blanchette.

Printed by Prevalence of Heparin in Samples Submitted for Lupus Anticoagulant Testing Nikhil A. Sangle MD FRCPath 1,3, George M.

ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience Alfonso Iorio, MD, PhD.

Clinical Pharmacy Part 2

SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.

Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.

+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.

Impact of E9 Addendum to Industry

Inhibitor development according to FVIII concentrate in PUPs: how to interpret current evidence? Alfonso Iorio Health Information Research Unit & Hamilton-Niagara.

Inhibitor reporting standardization in previously treated patients Alfonso Iorio ISTH SSC – Factor VIII/IX Saturday June 20, 2015 Room 10:20 Room: 718.

Non-adherence and its impact on treatment efficacy

WAPPS project (web accessible pharmacokinetics service)

H OW TO MEASURE PROGRESS IN THE PROVISION OF CARE FOR HEMOPHILIA Alfonso Iorio J Stonebraker, M Brooker, M Soucie. A workgroup of the Data and Demographics.

WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.

With Co-Chairs: Dr Chris Barnes and Dr Simon McRae

Annual Report Constitution Public Audit Act Public Finance Management Act Other legislation Minister of Finance Establishment and operations National.

FDA Draft Guidance Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved.

H ⊕ lger Schünemann, MD, PhD Professor and Chair, Dept. of Clinical Epidemiology & Biostatistics Professor of Medicine Michael Gent Chair in Healthcare.

Population-based PK in haemophilia A

LONDON BOROUGH OF MERTON: LOCAL INVOLVEMENT NETWORK (LINk) PUBLIC MEETING 8 February 2008 Richard Poxton Centre for Public Scrutiny National Team.

Working group on Pharmacokinetics and Population Pharmacokinetics of factor concentrates Alfonso Iorio, on behalf of the working group.

CURRENT ADVERSE EVENTS REPORTING IN HEMOPHILIA

A capacity building programme for patient representatives

Managing Inhibitor Risk in both PUPs and PTPs

How important is PK? How important is PK? Outline Alfonso Iorio

Patient Involvement in the HTA Decision Making Process

Evidence-Based Guidance on Comprehensive Care for Hemophilia

McMaster Hemophilia Research Group

Recording and Reporting Clinical Trial Results

Prof. Dr. Basavaraj K. Nanjwade

Overview Of CREW Activities July 2013 – June 2014

Support- IRDiRC Proposed Work Plan And Communication Strategy

Medical Device Evaluation Division,

Conflict of Interest Disclosure

Conflict of Interest Disclosure

Working Group on Pharmacokinetics and Population Pharmacokinetics

Copyright © 2017 American Academy of Pediatrics.

Systematic Reviews and Medical Policy Determinations

Connecting Pharmacokinetics and Phenotypes to Tailored Hemophilia Treatment 1. Pharmacokinetic approaches Professor Alfonso Iorio, MD, PhD, FRCPC.

Using pharmacokinetics to individualize hemophilia therapy

Women’s Health Technologies CRN

Progress Report on the Patient Reported Outcomes Harmonization Team

Conflict of Interest Disclosure:

ICTMS Communicating Trial Results to participants

Exploring Personalized Prophylaxis in Hemophilia A

Conflict of Interest Disclosure (over the past 24 months)

بسم الله الرحمن الرحیم.

Conflict of Interest Disclosure

CanMEDS Roles Covered X

Faculty Disclosure Slide Templates

Future Monitoring and Evaluation: Focus on results Antonella Schulte-Braucks Ines Hartwig ESF Evaluation Partnership Brussels 17 November 2011.

DISCLOSURE INFORMATION

Conflict of Interest Disclosure

DISCLOSURE INFORMATION

Speaking on Behalf of ASME

CanMEDS Roles Covered X

Draft Sectional Titles Schemes Management Bill, 2010 ( B )

Town and Parish Council Forum Jane Wormald & Patrick Conroy

Author 1 Name Company 1 Name Author 2 Name Company 2 Name

BioCapital Europe 2019, Amsterdam

Financial Disclosure Financial Interest / Affiliation

Evaluating the performance of advanced causal inference methods in real world data through large-scale replication of randomized controlled trials.

　Form1-A　There is no state of conflict of interest requiring disclosure

Aparna Raychaudhuri, Ph. D

CanMEDS Roles Covered X

Presentation transcript:

Alfonso Iorio, on behalf of the working group Working group on Pharmacokinetics and Population Pharmacokinetics of factor concentrates Alfonso Iorio, on behalf of the working group

DISCLOSURES Financial conflicts of interests McMaster University has received funds for research and service agreements from Bayer, Baxalta, Biogen, NovoNordisk, Octapharma, and Pfizer. Non-financial (intellectual) conflicts PI for the WAPPS project (www.wapps-hemo.org) No mention of unlicensed products

WORKING GROUP Core members Additional members PK and PopPK consultants A Iorio, V Blanchette, P Collins, K Fischer, J Blatny, E Neufeld Additional members D Lillicrap, D Hart, M Makris PK and PopPK consultants A Edginton, S Ito

Previous SSC Communications The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Morfini M, Lee M, Messori A. Thromb Haemost. 1991 Sep 2;66(3):384-6.

Previous SSC Communications Scientific and Standardization Committee Communication The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors On behalf of the Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis M. Lee, M. Morfini, S. Schulman, J. Ingerslev and the Factor VIII/Factor IX Scientific and Standardization Committee of the ISTH Posted on the ISTH SSC on March 21, 2001

Previous SSC Communications … the approaches recommended here are primarily intended for clinical trials of factor concentrates that are being compared to other, similar preparations. … studies on individual patients for diagnostic or therapeutic purposes may not necessarily be relevant to what is discussed here.

Previous SSC Communications

AIMS: Primary PK and PopPK estimates of factor concentrates: Reporting Interpretation Assessment in clinical practice Study design for “real world/PM” PopPK assessment

PK and PopPK estimation: AIMS: Secondary PK and PopPK estimation: During registration phase To compare different molecules Choice of time points ….

How (and whether) to best involve: PROCESS How (and whether) to best involve: Pharmaceutical companies PK/PopPK experts FDA / EMA PK/PopPK experts Authors of PK/PopPK published papers Patient representatives

PROGRESS 2 conference calls 1 panel survey Bi-monthly conference calls Review of the existing literature Review of regulators guidance Draft recommendations on primary goals

Thank you for attention Questions time Thank you for attention Slides posted on: http://hemophilia.mcmaster.ca/resources